Case Report of Rare Entity for Atypical Hemolytic Uremic Syndrome

Jump To References Section

Authors

  • PG Resident, Department of Medicine, Dr. Vasantrao Pawar Medical College, Nashik – 422003, Maharashtra ,IN
  • Assistant Professor, Department of Medicine, Dr. Vasantrao Pawar Medical College, Nashik – 422003, Maharashtra ,IN
  • Professor, Department of Medicine, Dr. Vasantrao Pawar Medical College, Nashik – 422003, Maharashtra ,IN
  • Professor, Department of Medicine, Dr. Vasantrao Pawar Medical College, Nashik – 422003, Maharashtra ,IN

DOI:

https://doi.org/10.18311/mvpjms/2020/v7i1/24147

Keywords:

Acute Kidney Injury, aHUS, Complement, Dialysis, Plasma Exchange, Thrombotic-Microangiopathy (TMA)
Nephrology

Abstract

Background: Atypical Haemolytic Uremic Syndrome (aHUS) is a genetic or acquired disorder of regulatory component of the complement system. It is associated with mutations in genes coding for complement components. The abnormality in components of complement makes it susceptible and predispose to chronic uncontrolled hyperactivation of the alternative complement pathway, which results in endothelial damage and microvascular thrombosis. This case report describes a patient diagnosed with Thrombotic Microangiopathy (TMA) due to factor H autoantibody having haemolytic anemia, thrombocytopenia and acute kidney injury. Patient's anemia and renal parameters improved after treatment with plasma exchange therapy. Conclusion: Atypical HUS must be strongly suspected in any patient who presents with nonspecific abdominal or respiratory symptoms along with anemia and thrombocytopenia. As extrarenal involvement is a rare entity of aHUS, the clinician should also keep a high index of suspicion to the possibility of thrombotic microangiopathy manifestation in almost any organ system. In a suspected or diagnosed case of aHUS, the development of new non renal symptoms and signs should prompt clinician for further evaluation to rule out ongoing thrombotic microangiopathy process.

Downloads

Published

2021-03-10

Issue

Section

Case Reports

 

References

Noris M, Remuzzi G. Atypical haemolytic uremic syndrome. New England Journal of Medicine. 2009: 1676-87. https:// doi.org/10.1056/NEJMra0902814. PMid:19846853.

Skorecki K, Chertow G. Brenner & Rector's The kidney. 10th ed. Philadelphia. Elsevier; 2016.

Caprioli J, Noris M, Brioschi S. Genetics of HUS: The impact of MCP, CFH and IF mutation son clinical presentation, response to treatment, and outcome. Blood. 2006; 108:1267-79. https://doi.org/10.1182/blood-2005-10007252. PMid:16621965 PMCid:PMC1895874

Loirat C, Noris M, Fremeaure-Bacchi V. Complement and the atypical haemolytic uremic syndrome in children. Pediatric Nephrology. 2008; 23(11):1957-72. https:// doi.org/10.1007/s00467-008-0872-4. PMid:18594873 PMCid:PMC6904381

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. New England Journal of Medicine. 2013; 368:23:2169-81. https:// doi.org/10.1056/NEJMoa1208981. PMid:23738544.

Bakr A. Haemolytic Uremic Syndrome in Children (19552015): A 60 Years Journey. Journal of Nephrology Research. 2015; 1:2.

Sinha A, Gulati A, Saini S. Indian HUS Registry: Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of antifactor H autoantibody associated haemolytic uremic syndrome in children. Kidney International. 2004; 85:1151-60. https://doi.org/10.1038/ ki.2013.373. PMid:24088957

Sibai BM. Imitators of severe pre-eclapsia/eclampsia. Clinics in Perinatology. 2004; 31:835-52. https://doi.org/10.1016/j. clp.2004.06.007. PMid:15519430.

McCrae KR, Cines DB. Thrombotic microangiopathy during pregnancy. Seminars in Hematology. 1997; 34:148.